These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 24878765)

  • 1. Genetic Addiction Risk Score (GARS): molecular neurogenetic evidence for predisposition to Reward Deficiency Syndrome (RDS).
    Blum K; Oscar-Berman M; Demetrovics Z; Barh D; Gold MS
    Mol Neurobiol; 2014 Dec; 50(3):765-96. PubMed ID: 24878765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurogenetic Impairments of Brain Reward Circuitry Links to Reward Deficiency Syndrome (RDS): Potential Nutrigenomic Induced Dopaminergic Activation.
    Blum K; Oscar-Berman M; Giordano J; Downs B; Simpatico T; Han D; Femino J
    J Genet Syndr Gene Ther; 2012 Oct; 3(4):. PubMed ID: 23264886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine Genetics and Function in Food and Substance Abuse.
    Blum K; Oscar-Berman M; Barh D; Giordano J; Gold M
    J Genet Syndr Gene Ther; 2013 Feb; 4(121):. PubMed ID: 23543775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biotechnical development of genetic addiction risk score (GARS) and selective evidence for inclusion of polymorphic allelic risk in substance use disorder (SUD).
    Blum K; Bowirrat A; Baron D; Lott L; Ponce JV; Brewer R; Siwicki D; Boyett B; Gondre-Lewis MC; Smith DE; Panayotis K T; Badgaiyan S; Hauser M; Fried L; A R; Downs BW; Badgaiyan RD
    J Syst Integr Neurosci; 2020 Aug; 6(2):. PubMed ID: 33614164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coupling Neurogenetics (GARS™) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms.
    Blum K; Simpatico T; Badgaiyan RD; Demetrovics Z; Fratantonio J; Agan G; Febo M; Gold MS
    J Reward Defic Syndr; 2015; 1(2):75-80. PubMed ID: 27617300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Search of Reward Deficiency Syndrome (RDS)-free Controls: The "Holy Grail" in Genetic Addiction Risk Testing.
    Blum K; Baron D; Lott L; Ponce JV; Siwicki D; Boyett B; Steinberg B; Modestino EJ; Fried L; Hauser M; Simpatico T; Downs BW; McLaughlin T; Hajela R; Badgaiyan RD
    Curr Psychopharmacol; 2020; 9(1):7-21. PubMed ID: 32432025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reward Deficiency Syndrome (RDS): A Cytoarchitectural Common Neurobiological Trait of All Addictions.
    Blum K; Bowirrat A; Braverman ER; Baron D; Cadet JL; Kazmi S; Elman I; Thanos PK; Badgaiyan RD; Downs WB; Bagchi D; Llanos-Gomez L; Gold MS
    Int J Environ Res Public Health; 2021 Nov; 18(21):. PubMed ID: 34770047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Manipulation of catechol-O-methyl-transferase (COMT) activity to influence the attenuation of substance seeking behavior, a subtype of Reward Deficiency Syndrome (RDS), is dependent upon gene polymorphisms: a hypothesis.
    Blum K; Chen TJ; Meshkin B; Waite RL; Downs BW; Blum SH; Mengucci JF; Arcuri V; Braverman ER; Palomo T
    Med Hypotheses; 2007; 69(5):1054-60. PubMed ID: 17467918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Future is Now for Precision Genomic Addiction Medicine as a Frontline Modality for Inducing "Dopamine Homeostasis" in Reward Deficiency Syndrome (RDS).
    Gilley ED; Bowirrat A; Gupta A; Giordano J; A Dennen C; R Braverman E; D Badgaiyan R; McLaughlin T; Baron D; Blum K
    Curr Pharm Biotechnol; 2023 Apr; ():. PubMed ID: 37102488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should Reward Deficiency Syndrome (RDS) Be Considered an Umbrella Disorder for Mental Illness and Associated Genetic and Epigenetic Induced Dysregulation of Brain Reward Circuitry?
    Blum K; Dennen CA; Elman I; Bowirrat A; Thanos PK; Badgaiyan RD; Downs BW; Bagchi D; Baron D; Braverman ER; Gupta A; Green R; McLaughlin T; Barh D; Gold MS
    J Pers Med; 2022 Oct; 12(10):. PubMed ID: 36294858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurogenetics and clinical evidence for the putative activation of the brain reward circuitry by a neuroadaptagen: proposing an addiction candidate gene panel map.
    Chen TJ; Blum K; Chen AL; Bowirrat A; Downs WB; Madigan MA; Waite RL; Bailey JA; Kerner M; Yeldandi S; Majmundar N; Giordano J; Morse S; Miller D; Fornari F; Braverman ER
    J Psychoactive Drugs; 2011; 43(2):108-27. PubMed ID: 21858957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Common Neurogenetic Diagnosis and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape.
    Blum K; Febo M; Badgaiyan RD; Demetrovics Z; Simpatico T; Fahlke C; M OB; Li M; Dushaj K; Gold MS
    Curr Neuropharmacol; 2017; 15(1):184-194. PubMed ID: 27174576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypodopaminergia and "Precision Behavioral Management" (PBM): It is a Generational Family Affair.
    Fried L; Modestino EJ; Siwicki D; Lott L; Thanos PK; Baron D; Badgaiyan RD; Ponce JV; Giordano J; Downs WB; Gondré-Lewis MC; Bruce S; Braverman ER; Boyett B; Blum K
    Curr Pharm Biotechnol; 2020; 21(6):528-541. PubMed ID: 31820688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Shared Molecular and Genetic Basis for Food and Drug Addiction: Overcoming Hypodopaminergic Trait/State by Incorporating Dopamine Agonistic Therapy in Psychiatry.
    Gold MS; Badgaiyan RD; Blum K
    Psychiatr Clin North Am; 2015 Sep; 38(3):419-62. PubMed ID: 26300032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Benefits of Genetic Addiction Risk Score (GARS
    Blum K; Modestino EJ; Gondre-Lewis M; Chapman EJ; Neary J; Siwicki D; Baron D; Hauser M; Smith DE; Roy AK; Thanos PK; Steinberg B; McLaughlin T; Fried L; Barh D; Dunston GA; Badgaiyan RD
    Int J Genom Data Min; 2018; 2018(1):. PubMed ID: 30198022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuro-chemical activation of brain reward meso-limbic circuitry is associated with relapse prevention and drug hunger: a hypothesis.
    Blum K; Gold MS
    Med Hypotheses; 2011 Apr; 76(4):576-84. PubMed ID: 21306831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generational association studies of dopaminergic genes in reward deficiency syndrome (RDS) subjects: selecting appropriate phenotypes for reward dependence behaviors.
    Blum K; Chen AL; Oscar-Berman M; Chen TJ; Lubar J; White N; Lubar J; Bowirrat A; Braverman E; Schoolfield J; Waite RL; Downs BW; Madigan M; Comings DE; Davis C; Kerner MM; Knopf J; Palomo T; Giordano JJ; Morse SA; Fornari F; Barh D; Femino J; Bailey JA
    Int J Environ Res Public Health; 2011 Dec; 8(12):4425-59. PubMed ID: 22408582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurogenetics and gene therapy for reward deficiency syndrome: are we going to the Promised Land?
    Blum K; Thanos PK; Badgaiyan RD; Febo M; Oscar-Berman M; Fratantonio J; Demotrovics Z; Gold MS
    Expert Opin Biol Ther; 2015 Jul; 15(7):973-85. PubMed ID: 25974314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reward deficiency syndrome: genetic aspects of behavioral disorders.
    Comings DE; Blum K
    Prog Brain Res; 2000; 126():325-41. PubMed ID: 11105655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Genetic Testing in Reward Deficiency Syndrome (RDS): Facts and Fiction.
    Blum K; Badgaiyan RD; Agan G; Fratantonio J; Simpatico T; Febo M; Haberstick BC; Smolen A; Gold MS
    J Reward Defic Syndr; 2015; 1(1):65-68. PubMed ID: 26052557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.